Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Calcium and bone density

This article was originally published in The Tan Sheet

Executive Summary

Calcium supplementation beneficially affects bone density in healthy women over age 55, according to a study in the September American Journal of Medicine. The randomized controlled trial of 1,471 healthy, postmenopausal women took place over five years in New Zealand. Subjects received either 1 g of elemental calcium daily (as citrate) or identical placebo, Ian Reid, MD, et al., Department of Medicine, University of Auckland, New Zealand, state. Calcium had a significant beneficial effect on bone density with between-group differences at five years showing increases of 1.8% for the spine, 1.6% for the hip and 1.2% for the total body, researchers state. However, the beneficial effects on bone density were tempered with the "lack of a clear-cut effect of calcium on fracture rates," which may be attributed to the poor rates of long-term compliance, Reid et al. say. The study is the longest and largest calcium-only study yet published and "as such, it is able to establish the beneficial effects of calcium supplementation on bone density with greater certainty than has been possible thus far," according to Reid et al....

You may also be interested in...

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.

Rapid Biopharma Response To COVID-19 Enabled By Decades Of R&D Investment, Firms Say

Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts